• The Effects of Osmogant and Binder in Membrane on Nifedipine Release from Osmotic Granule
  • Jeong SC, Cho YH, Kim MS, Lee B, Khang G, Rhee JM, Lee HB
  • 니페디핀의 삼투성 과립에서 삼투염과 반투막내의 결합제 종류가 약물방출에 미치는 영향
  • 정성찬, 조영호, 김문석, 이봉, 강길선, 이종문, 이해방
Abstract
To improve the type error of osmotic tablet which is one of the drug delivery system, osmotic granule could be manufactured by fluidized bed coating. It has drug layer containing different amount of osmogant and is coated with membrane including different types of binder. We confirmed that the morphology of osmotic granule was different at each coating step. The more amount of osmotic agent, the faster drug release was observed due to increasing the driving force for drug release from osmotic granule. And drug release from osmotic granule coated with membrane using different types of binder was differed by solubility of binders to water. The formation of pore in membrane was confirmed by SEM and DSC. Membrane using water soluble binder released more amount of drug. From these results, we assured that difference of osmotic pressure between the inside and the outside of granule and porosity of membrane have an effect on drug release from osmotic granule.

약물전달 시스템 중의 하나인 삼투압정의 단점을 보완하기 위해 많은 장점을 가지는 유동층 코팅 기술을 이용하여 내부의 삼투염의 양과 반투막 내의 결합제의 종류가 다른 삼투압을 이용하는 과립을 제조하였다. 얻어진 과립은 코팅 단계에 따라 과립의 형태가 상이하였으며, 약물층에 포함된 삼투염의 양이 많을수록 많은 양의 약물을 방출하였다. 이는 과립의 내부와 외부의 삼투압 차이가 커져서 약물을 방출시키는 추진력이 증가하였기 때문으로 사료된다. 또한 반투막 의 결합제 종류에 따른 약물의 방출은 결합제의 물에 대한 용해도에 따라 달라짐을 확인할 수 있었다. 반투막 내의 다공 의 형성은 SEM과 DSC를 이용하여 확인하였으며, 물에 대한 용해도가 큰 결합제를 사용한 반투막이 더 많은 양의 약물 을 방출함을 확인하였다. 이 실험을 통해 삼투압을 이용한 과립의 약물방출은 과립 내부와 외부의 삼투압 차이와 반투막의 다공도에 의해 영향을 받는다는 것을 확인하였다.

Keywords: osmotic drug delivery system; granulation; fluidized bed coating; semipermeable membrane

References
  • 1. Perkins L, Peer C, Fleming VPumps/osmotic-alzet system, in Encyclopedia of Controlled Drug Delivery, E. Mathiowitz, Ed., Wiley, New York, U.S.A, 2, 900 (1999)
  •  
  • 2. Magruder JPumps/osmotic-VITS veterinary implant, in Encyclopedia of Controlled Drug Delivery, E. Mathiowitz, Ed., Wiley, New York, U.S.A, 2, 906 (1999)
  •  
  • 3. Wright JC, Stevenson CL, Stewart GRPumps/osmotic-DUROS osmotic implant for humans, in Encyclopedia of Controlled Drug Delivery, E. Mathiowitz, Ed., Wiley, New York, U.S.A, 2, 909 (1999)
  •  
  • 4. Wright JPumps/osmotic-ruminal osmotic bolus, in Encyclopedia of Controlled Drug Delivery, E. Mathiowitz, Ed., Wiley, New York, U.S.A, 2, 915 (1999)
  •  
  • 5. Theeuwes F, Wong PSL, Burkoth TL, Fox DAOsmotic systems for colon-targeted drug delivery, in Colonic Drug Absorption and Metabolism, P.R. Bieck, Ed., Marcel Dekker, New York, U.S.A, 137 (1993)
  •  
  • 6. Amkraut A, Eckenhoff JB, Nichols K, Adv. Drug Deliv. Rev., 4, 255 (1990)
  •  
  • 7. Theeuwes F, J. Pharm. Sci., 64, 1987 (1975)
  •  
  • 8. Wong PSL, Barclay BL, Deters JC, TheeuwesU.S. Patent 4,765,989 (1986)
  •  
  • 9. Theeuwes F, Pharm. Int., 5, 293 (1984)
  •  
  • 10. Theeuwes FNovel Drug Delivery Systems, ADIS Press, 157 (1981)
  •  
  • 11. Kage H, Abe R, Hattanda R, Zhou T, Ogura H, Matsuno Y, Powder Technol., 130(1-3), 203 (2003)
  •  
  • 12. Deast PBMicroencapsulation and Related Drug Processes, Marcel Dekker, New York (1984)
  •  
  • 13. Liu L, Khang G, Rhee JM, Lee HB, Polym.(Korea), 7, 289 (1999)
  •  
  • 14. Liu L, Khang G, Rhee JM, Lee HB, Biomater. Res, 3, 47 (1999)
  •  
  • 15. Liu L, Khang G, Rhee JM, Lee HB, Bio-Med. Mater. Eng., 9, 297 (1999)
  •  
  • 16. Liu L, Khang G, Rhee JM, Lee HB, J. Control. Release, 67, 309 (2000)
  •  
  • 17. Liu L, Ku J, Khang G, Lee B, Rhee JM, Lee HB, J. Control. Release, 68, 145 (2000)
  •  
  • 18. Khang G, Ku J, Lee B, Lee HB, Biomater. Res., 4, 20 (2000)
  •  
  • 19. Lui L, Khang G, Rhee JM, Lee HB, Acta Pharmacol. Sin., 38, 620 (2003)
  •  
  • 20. Lui L, Xu Q, Khang G, Rhee JM, Lee HB, Acta Pharmacol. Sin., 38, 966 (2003)
  •  
  • 21. Sudsakorn K, Turton R, Powder Technol., 110(1-2), 37 (2000)
  •  
  • 22. Kage H, Abe R, Hattanda R, Zhou T, Ogura H, Matsuno Y, Powder Technol., 130(1-3), 203 (2003)
  •  
  • 23. Donbrow MMicroencapsulation and Nanoparticles in Medicine and Pharmacy, CRC Press, Boca Raton, FL (1991)
  •  
  • 24. Ho H, Chen C, Sheu M, J. Control. Release, 68, 433 (2000)
  •  
  • 25. Wang Y, Winnik MA, Macromolecules, 23, 4731 (1990)
  •  
  • 26. Siepmann J, Lecomte F, Bodmeirer R, J. Control. Release, 60, 379 (1999)
  •  
  • 27. Jeong SC, Chon SK, Jo YH, Kim MS, Lee B, Khang G, Lee HB, Polym.(Korea), 29(3), 288 (2005)
  •  
  • 28. Colombo P, Bettimi R, Massimo G, Catellani PL, Santi P, Peppas NA, J. Pharm. Sci., 84, 991 (1995)
  •  
  • 29. Rowe RC, Int. J. Pharm., 29, 37 (1986)
  •  
  • 30. Wade A, Weller PJHandbook of Pharmaceutical Excipients, Am. Pharm. Assoc., Washington DC (1994)
  •  
  • 31. Harris MR, Ghebre-Sellassie I, Nesbitt RU, Pharm. Technol., 10, 102 (1986)
  •  
  • 32. Meier MM, Kanis LA, Soldi V, Int. J. Pharm., 278, 99 (2004)
  •  
  • 33. Auda HSA, Najjar TA, Al-Khamis KI, AI-Hadiya BM, Ghilzai NM, AI-Fawzan NF, J. Pharm. Biomed. Anal., 22, 241 (2000)
  •  
  • 34. Niopas I, Dafrsios AC, J. Pharm. Biomed. Anal., 32, 1213 (2003)
  •  
  • Polymer(Korea) 폴리머
  • Frequency : Bimonthly(odd)
    ISSN 0379-153X(Print)
    ISSN 2234-8077(Online)
    Abbr. Polym. Korea
  • 2024 Impact Factor : 0.6
  • Indexed in SCIE

This Article

  • 2006; 30(2): 112-117

    Published online Mar 25, 2006

  • Received on Aug 5, 2005
  • Accepted on Mar 13, 2006